Comparison of the size distributions and immunogenicity of human papillomavirus type 16 L1 virus-like particles produced in insect and yeast cells

다국어 초록 (Multilingual Abstract)

Insect and yeast cells are considered theexpression systems of choice for producing virus-likeparticles (VLPs), and numerous types of VLPs have beenproduced in these systems. However, previous studies wererestricted to identifying the characteristics of individualVLP preparations. No direct comparison of the structuresand immunogenic properties of insect and yeast-derivedVLPs has so far been made. In the present study, the sizedistribution and immunogenic properties of human papillomavirustype 16 (HPV16) L1 VLPs produced in Spodopterafrugipedra-9 insect cells and Saccharomycescerevisiae were compared. The insect cell-derived VLPswere larger than the yeast ones (P\0.0001), with mediansizes of 34 and 26 nm, respectively. In addition, the insectderivedVLPs appeared to be more diverse in size than theyeast-derived VLPs. Immunization of mice with 30 ng perdose of VLPs elicited 2.7- and 2.4-fold higher anti-HPV16L1 IgG and anti-HPV16 neutralizing antibody titers thanimmunization with the same amounts of the yeast-derivedVLPs after the 4th immunizations, respectively. Our resultssuggest that the choice of expression system criticallyaffects the particle size and immunogenic property ofHPV16 L1 VLPs.

참고문헌 (Reference)

1 Kim HJ, "Yeast as an expression system for producing virus-like particles: what factors do we need to consider?" 64 : 111-123, 2017

2 Van Oers MM, "Thirty years of baculovirus-insect cell protein expression: from dark horse to mainstream technology" 96 : 6-23, 2015

3 Chames P, "Therapeutic antibodies: successes, limitations and hopes for the future" 157 : 220-233, 2009

4 Buck CB, "The papillomavirus major capsid protein L1" 445 : 169-174, 2013

5 Kim HJ, "The concentration of carbon source in the medium affects the quality of virus-like particles of human papillomavirus type 16 produced in Saccharomyces cerevisiae" 9 : e94467-, 2014

6 Kim HJ, "The composition of the carbon source and the time of cell harvest are critical determinants of the final yield of human papillomavirus type 16 L1 protein produced in Saccharomyces cerevisiae" 80 : 52-60, 2011

7 Kim HJ, "The Choice of resinbound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles" 7 : e35893-, 2012

8 Kanesashi SN, "Simian virus 40 VP1 capsid protein forms polymorphic assemblies in vitro" 84 : 1899-1905, 2003

9 Zahin M, "Scalable production of HPV16 L1 protein and VLPs from tobacco leaves" 11 : e0160995-, 2016

10 Schadlicha L, "Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity" 27 : 1511-1522, 2009

11 Rizk RZ, "Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types" 89 : 117-129, 2008

12 Patel MC, "Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles" 130 : 213-218, 2009

13 Kim HJ, "One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae" 70 : 68-74, 2010

14 Effio CL, "Next generation vaccines and vectors: designing downstream processes for recombinant protein-based virus-like particles" 10 : 715-727, 2015

15 Cardone G, "Maturation of the human papillomavirus 16 capsid" 5 : e01104-e01114, 2014

16 Fernandes F, "Insect cells as a production platform of complex viruslike particles" 12 : 225-236, 2013

17 Carter JJ, "Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1" 77 : 11625-11632, 2003

18 Crosbie EJ, "Human papillomavirus and cervical cancer" 382 : 889-899, 2013

19 Abdoli A, "Human papillomavirus Type16-L1 VLP production in insect cells" 16 : 891-895, 2013

20 Freivalds J, "Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris" 75 : 218-224, 2011

21 Shank-Retzlaff ML, "Evaluation of the thermal stability of Gardasil (R)" 2 : 147-154, 2006

22 Karageosov I, "Electron microscopic detection of viruses in cervix papilloma" 107 : 187-191, 1985

23 Don Yong Chang, "Effects of Downstream Processing on Structural Integrity and Immunogenicity in the Manufacture of Papillomavirus Type 16 L1 Virus-like Particles" 한국생물공학회 17 (17): 755-763, 2012

24 Mach H, "Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs)" 95 : 2195-2206, 2006

25 Shirbaghaee Z, "Different applications of viruslike particles in biology and medicine: vaccination and delivery systems" 105 : 113-132, 2016

26 Ryding J, "Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles" 88 : 792-802, 2007

27 김형진, "Current status and future prospects for human papillomavirus vaccines" 대한약학회 40 (40): 1050-1063, 2017

28 Zeltins A, "Construction and characterization of virus-like particles: a review" 53 : 92-107, 2013

29 Einstein MH, "Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years" 5 : 705-719, 2009

30 Zhao QJ, "Characterization of virus-like particles in GARDASIL (R) by cryo transmission electron microscopy" 10 : 734-739, 2014

31 White WI, "Characterization of a major neutralizing epitope on human papillomavirus type 16 L1" 73 : 4882-4889, 1999

32 Le Tallec D, "Cervarix (TM), the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions" 5 : 467-474, 2009

33 Zahid M, "Assessing stability and assembly of the hepatitis B surface antigen into virus-like particles during down-stream processing" 33 : 3739-3745, 2015

34 김형진, "Assembly of the Capsid Protein of Red-spotted Grouper Nervous Necrosis Virus during Purification, and Role of Calcium Ions in Chromatography" 한국생물공학회 21 (21): 373-380, 2016